Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Researchers at NYU Langone Health created an artificial intelligence algorithm for routine computed tomography scans that ...

Magnetic resonance imaging (MRI) holds great potential to spare men with suspected prostate cancer a painful biopsy. In our ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Otherwise, because osteoporosis is typically asymptomatic, men (and women, who are also undertested and undertreated) don’t ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...

A multicenter study led by London Health Sciences Centre Research Institute (LHSCRI), Lawson Research Institute of St. Joseph ...